All In Biotech

Drug Trial Radar · NCT07938034

A Study of SYH2053 Injection in Participants With Renal Impairment Compared to Participants With Normal Renal Function

A Phase I Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of SYH2053 Injection in Participants With Normal Renal Function and Renal Impairment: A Non-randomized, Open-label, Parallel-Controlled, Single-Dose Study

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

Jul 15, 2027

Study completion Sep 15, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of SYH2053 injection in participants with moderate, and severe renal impairment compared to participants with normal renal function.

Conditions

  • Renal Impairment

Interventions

  • SYH2053Drug

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax)Time frame: Time Frame: Pre-dose and multiple timepoints up to 4 days
  2. Area under the curve of the plasma concentration (AUC)Time frame: Pre-dose and multiple timepoints up to 4 days
  3. Time to reach maximum plasma concentration (Tmax)Time frame: Pre-dose and multiple timepoints up to 4 days
  4. Terminal half-life (t1/2)Time frame: Pre-dose and multiple timepoints up to 4 days
  5. Apparent total clearance (CL/F)Time frame: Pre-dose and multiple timepoints up to 4 days
  6. Apparent volume of distribution (Vz/F)Time frame: Pre-dose and multiple timepoints up to 4 days
  7. Amount excreted unchanged in urine (Ae) of SYH2053 over 72 hours post-doseTime frame: Pre-dose and multiple timepoints up to 4 days
  8. Fraction excreted (fe) of SYH2053 over 72 hours post-doseTime frame: Pre-dose and multiple timepoints up to 4 days
  9. Renal clearance (CLr) of SYH2053Time frame: Pre-dose and multiple timepoints up to 4 days
  10. The serum Low-density lipoprotein cholesterol (LDL-C) levelTime frame: through study completion, an average of 6 months
  11. The serum PCSK9 levelTime frame: through study completion, an average of 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.